Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen

Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, HER2 overexpressing breast cancer cells respond poorly to tamoxifen therapy presumably by pass. The molecular mechanisms underlying development of tamoxifen resistance have not been well established. Rec...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Cancer Res
Autores principales: Yin, Li, Pan, Xiaohua, Zhang, Xin-Tian, Guo, Yu-Ming, Wang, Zhao-Yi, Gong, Yaoqin, Wang, Molin
Formato: Artigo
Lenguaje:Inglês
Publicado: e-Century Publishing Corporation 2015
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396031/
https://ncbi.nlm.nih.gov/pubmed/25973295
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares